Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-08-08 18:31 |
Biophytis – Shareholders Approve All Resolutions at the Extraordinary General M…
|
English | 93.5 KB | ||
| 2019-08-08 18:31 |
Résultats de l’Assemblée Générale Extraordinaire du 8 août 2019 - Adoption de l…
|
French | 173.5 KB | ||
| 2019-07-25 07:30 |
Biophytis annonce le retrait de son Offre Globale sur le Nasdaq
|
French | 189.2 KB | ||
| 2019-07-25 07:30 |
Biophytis Withdraws Registration Statement for Global Offering
|
English | 183.5 KB | ||
| 2019-07-12 02:02 |
Biophytis annonce le dépôt d’un avenant à sa déclaration d’enregistrement pour …
|
French | 242.3 KB | ||
| 2019-07-12 02:02 |
Biophytis Announces Filing of Amendment to Registration Statement for Global Of…
|
English | 227.4 KB | ||
| 2019-07-09 00:39 |
Biophytis Announces the Launch of its Public Offering on Nasdaq
|
English | 225.7 KB | ||
| 2019-06-28 17:42 |
Biophytis Announces Results of 2019 Annual General Meeting of Shareholders
|
English | 180.0 KB | ||
| 2019-06-28 17:42 |
Résultats de l’Assemblée Générale 2019
|
French | 226.3 KB | ||
| 2019-06-26 18:12 |
Biophytis a réalisé une présentation orale et présenté un poster au congrès Mac…
|
French | 224.1 KB | ||
| 2019-06-26 18:12 |
Biophytis Announces it Presented One Oral and One Poster Presentation at the Ma…
|
English | 176.8 KB | ||
| 2019-06-12 07:30 |
Biophytis annonce une collaboration avec l’Association Française contre les Myo…
|
French | 241.9 KB | ||
| 2019-06-12 07:30 |
Biophytis Enters into a Collaboration with the French Muscular Dystrophy Associ…
|
English | 195.8 KB | ||
| 2019-06-07 20:24 |
Biophytis étend le champ des responsabilités de Daniel Schneiderman qui devient…
|
French | 217.9 KB | ||
| 2019-06-07 20:24 |
Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer
|
English | 163.7 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
